Stock Ratings / Health Care / AGEN / options

SCTX (50) ALEC (32) XFOR (35) IRLA (32) ⌘ Pro Terminal →

Agenus Inc. (AGEN) Options Positioning, Max Pain & Unusual Sweeps

$7.09 -0.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.07

Agenus Inc. (AGEN) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $320.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $7.07 (-0.29%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-14.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AGEN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (26/100 Composite)

🔍 WHY AGEN SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (31% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (23% of score)

FRED Regime × Technicals: 58% of 52W Range • RSI-14 at 46.7 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$7.67-21.3% Next Q

Q2 (-2Q)

Grade E$6.04+4.8% Next Q

Q3 (-1Q)

Grade E$6.33+12% Next Q

Current

Grade E$7.09-10.5% Hist 90D α

Trajectory: E (34) → E (26)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AGEN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AGEN currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.59) and Max Pain ($7.44) forces dealer call-delta covering toward $10.83.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AGEN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AGEN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 26%NO 74%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (AGEN)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for AGEN.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AGEN)

✓Walkthrough of AGEN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AGEN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +81.33%📐 HORIZONTAL RANGE

2026-10-30O $6.87H $7.09L $6.69C $7.09VOL 564.4K

RES: $11.16SUP: $5.93SMA50: $7.59SMA200: $4.93

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AGEN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AGEN Butterfly Map → + Track AGEN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +10.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AGEN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AGEN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AGEN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AGEN)

Health Care Rank #986 of 1016 ⚔️ SCTX vs AGEN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AGEN vs. SCTX, ALEC, XFOR, IRLA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Agenus Inc. (AGEN) ranks #986 by composite RQD confidence (26/100, grade E) and #514 by equity capitalization ($320.2M). Within this direct 5-issuer industry benchmark cohort, AGEN leads on earnings valuation at N/A trailing P/E, while AGEN leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. SCTX currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with AGEN at 26/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AGEN ACTIVE Agenus Inc.	E	26/100	—	96.0%	-35.0%	-0.56%	$320.2M	Benchmark Subject
SCTX Scribe Therapeutics Inc.	D	50/100	—	—	—	-0.57%	$330.2M	/sctx-vs-agen →
ALEC Alector Inc.	E	32/100	—	—	-35.0%	-0.44%	$332.1M	/alec-vs-agen →
XFOR X4 Pharmaceuticals Inc.	D-	35/100	—	83.6%	-35.0%	+0.30%	$333.1M	/xfor-vs-agen →
IRLA IRulya Therapeutics Inc.	E	32/100	—	—	-35.0%	-4.05%	$342.8M	/irla-vs-agen →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001098972

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Agenus Inc. (AGEN) reported GAAP revenue of $114.2M (+10.4% vs. FY2024 revenue of $103.5M , and -26.9% cumulative change since FY2023) , GAAP net income of -$3.1M, operating cash flow of -$77.2M, and free cash flow of -$77.2M (+51.4% YoY). On the balance sheet, AGEN closed FY2025 with $226.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$114.2M	-$3.1M	-$77.2M	-$77.2M	$226.8M	$0
FY2024 (FY)	2024-12-31	$103.5M	-$232.3M	-$158.3M	-$158.9M	$226.3M	$30.5M
FY2023 (FY)	2023-12-31	$156.3M	-$257.4M	-$224.2M	-$224.2M	—	—

3. AGEN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Agenus Inc. (NASDAQ: AGEN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $7.09 (-0.56% 1D, market cap $320.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AGEN ranks #986 in composite RQD confidence.

How does AGEN compare to SCTX and ALEC in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AGEN carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, SCTX (Scribe Therapeutics Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $330.2M) and ALEC (Alector Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $332.1M). Among the 5-stock peer group, AGEN leads on earnings multiple (N/A) while AGEN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AGEN?

Per AGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001098972), Agenus Inc. generated $114.2M in revenue (+10.4% YoY), -$3.1M in net income, and -$77.2M in free cash flow against $226.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AGEN trading relative to its 50-day, 200-day, and 52-week technical levels?

AGEN last traded at $7.09 (-0.56% on volume of 625,488 shares), positioning the stock -6.59% below its 50-day simple moving average ($7.59) and +43.81% above its 200-day simple moving average ($4.93). Across its 52-week range of $2.71 to $10.31, AGEN sits at the 57.6% percentile with a 14-day RSI of 46.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.20 to $7.98).

AGEN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is AGEN's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for AGEN.

Direct Sub-Reports: AGEN RQD Cockpit AGEN 12M Forecast AGEN Earnings & Move AGEN Dividends & DRIP AGEN Insiders & 13F AGEN Whale Options AGEN Profit Sankey AGEN News & Why